Lipoprotein (A) in clinical practice

Journal of the Pakistan Medical Association

Volumn 64, Issue 4, 2014, Pages 447-450

  Jayasinghe, Rohan ^a   Craig, Ian Hamilton ^b   Mohan, Raj Kamal Alfred ^a  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Apolipoprotein B; Cardiovascular disease; Lipoprotein (a); Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANACETRAPIB; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; ATORVASTATIN; CARNITINE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; EVOLOCUMAB; FISH OIL; FOSINOPRIL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; MARKER; MIPOMERSEN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PALM OIL; PLASMINOGEN; TISSUE PLASMINOGEN ACTIVATOR;

APHERESIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHEMICAL STRUCTURE; CHROMOSOME 6Q; CORONARY ARTERY DISEASE; DISULFIDE BOND; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; VEGETARIAN DIET;

CORONARY ARTERY DISEASE; HUMANS; LIPOPROTEIN(A); RISK FACTORS;

EID: 84897129444     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Lipoprotein (a) and risk of myocardial infarction--genetic epidemiologic evidence of causality. Scand J Clin Lab Invest 2011; 71: 87-93.
2. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp (a) glycoprotein phenotypes. Inheritance and relation to Lp (a)- lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458-65.
3. Berg K. A new serum type system in man: the LP system. Acta Pathol Microbiol Scand 1963; 59: 362-82.
4. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-7.
5. Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein (a): insights into lipoprotein(a) assembly & pathogenicity. Curr Opin Lipidol 2004; 15: 167-74.
6. Kostner KM, Kostner GM. Lipoprotein (a): Still an enigma? Curr Opin Lipidol 2002; 13: 391-6.
7. Sotiriou SN, Orlova VV, Al-Fakhri N, Ihanus E, Economopoulou, Isermann B, et al. Lipoprotein(a) in atherosclerotic plaques recruitsinflammatory cells through interaction with Mac-1 integrin. FASEB J 2006; 20: 559-61.
8. Ichikawa T, Unoki H, Sun H, Shimoyamada H, Marcovina S, Shikama H, et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am. J Pathol 2002; 160: 227-36.
9. Enas EA, Senthilkumar A. Coronary Artery Disease in Asian Indians: An Update and Review. Int J Cardiol 2001; 1: 2.
10. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353: 46-57.
11. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol 2008; 19: 369-77.
12. Sandholzer C, Halman D, Saha N, Sigurdsson G, Lackner C, Császár A, et al. Effect of apolipoprotein (a) polymorphism on the lipoprotein (a) concentration in seven ethnic groups. Human Genet 1991; 86: 607-14.
13. Cobbaert C, Mulder P, Lindemans J, Kesteloot H. Serum LP(a) levels in African aboriginal Pygmies and Bantus, compared with Caucasian and Asian population samples. J Clin Epidemiol 1997; 50: 1045-53.
14. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, et al. Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2012; 125: 241-9.
15. Ridker PM, Hennekens CA, Stampfer MJ. A prospective study of Lp(a) and the risk of myocardial infarction. JAMA 1993; 270: 2195-9.
16. S. Marcovina ML, Koschinsky J. Albers JJ, Skarlatos S. Report of the National Heart Lung and Blood Institute workshop on lipoprotein(a) and cardiovascular disease. Recent advances and future directions. Clin Chem 2003; 49: 1788-96.
17. Clarke R1, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, et al, PROCARDIS Consortium. Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease, N Engl J Med 2009; 361: 2518-28.
18. Dahlen CG. Lipoprotein(a) in cardiovascular disease: Review article and viewpoint. Atherosclerosis 1994; 108: 111-26.
19. Takagi H. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int J Cardiol 2012; 154: 183-6.
20. Schlueter W, Keilani T, Batlle DC. Metabolic effects of ACE inhibitors: focus on the reduction of cholesterol and lipoprotein (a) by fosinopril. Am J Cardiol 1993; 72: 37-44.
21. Jayasinghe SR, Kostner K, Lp(a) and coronary disease:Rules of engagement, when to measure and how to treat?South African Med J 2009; 99: 7502-4.
22. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J 2010; 31: 2844-53.
23. Hoffmann U1, Derfler K, Haas M, Stadler A, Brady TJ, Kostner K. Effects of combined low-density lipoprotein apheresis and aggressive statin therapy on coronary calcified plaque as measured by computed tomography. Am Jo Cardiol 2003; 91: 461-4.
24. Salonen EM, Jauhiainen M, Zardi L, Vaheri A, Ehnholm C. Lipoprotein(a) binds to fibronectin and has serine proteinase activity capable of cleaving it. EMBO J 1989; 8: 4035-40.
25. Joy TR. Novel therapeutic agents for lowering low density lipoprotein cholesterol. Pharmacol Ther 2012; 135: 31-43.
26. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, et al. Efficacy and safety of the cholesterol ethyl transfer protein inhibitor anacetrapib as monotherapy and coadministered with artovastatin in dyslipidemic patients. Am Heart J 2009; 157: 352-60.
27. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), hormone replacement therapy, and risk of future cardiovascular events. J Am Coll Cardiol 2008; 52: 124-31.
28. Harman SM, Vittinghoff E, Brinton EA, Budoff MJ, Cedars MI, Lobo RA, et al. Timing and duration of menopausal hormone treatment may affect cardiovascular outcomes. Am J Med 2011; 124: 199-205.
29. Sharpe PC, Young IS, Evans AE. Effect of moderate alcohol consumption on Lp(a) lipoprotein concentrations: Reduction is supported by other studies. BMJ (Clinical Research Ed 1998; 316: 1675.
30. Marcovina SM, Kennedy H, Bittolo Bon G, Cazzolato G, Casiglia E, Puato M, et al Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: The Lugalawa Study. Arterioscler Thromb Vasc Biol 1999;19: 1250-6.
31. de Backer G, Ambrosioni E, Johnson KB, Brotons C, Cifkova R, Dallongeville J, et al, European guidelines on cardiovascular prevention in clinical practice, Eur J Prevent Cardiol 2003; 24: 1601-10.
32. Tsimikas S, Witztum J, Catapano A. Effect of Mipomersen on Lipoprotein (a) in patients with Hypercholesterolemia across four phase 3 studies. J Am Coll Cardiol 2012; 59: E1494.
33. Raal F1, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126: 2408-17.